Hairy Cell Leukemia
Associated Genetic Biomarkers
NCI Definition: A neoplasm of small B-lymphocytes with "hairy" projections in bone marrow, spleen, and peripheral blood. Most patients present with splenomegaly and pancytopenia. (WHO, 2001) 
Hairy cell leukemias most frequently harbor alterations in BRAF .
BRAF V600E, BRAF Mutation, BRAF Exon 15 Mutation, and BRAF Codon 600 Missense are the most common alterations in hairy cell leukemia .
Of the biomarker-directed therapies for hairy cell leukemia, 0 are FDA-approved in at least one setting and 1 has NCCN guidelines in at least one setting .
Disease is predicted to be sensitive: -
Sample must match all of the following:
|Clinical Setting(s): Refractory (NCCN), Relapse (NCCN)|
|Note: Hairy Cell Leukemia, a subtype of Mature B-Cell Lymphoma/Leukemia, harboring BRAF V600E mutation responded to vemurafenib in two patients who had refractory disease or were in relapse after conventional therapies.|
There are 14 clinical trials for hairy cell leukemia, of which 13 are open and 1 is completed or closed. Of the trials that contain hairy cell leukemia as an inclusion criterion, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 9 are phase 2 (9 open).
BRAF and MYC are the most frequent gene inclusion criteria for hairy cell leukemia clinical trials .
Rituximab, bendamustine, and cladribine are the most common interventions in hairy cell leukemia clinical trials.
Significant Genes in Hairy Cell Leukemia
BRAF is mutated in 58.33% of hairy cell leukemia patients .
BRAF is an inclusion eligibility criterion in 3 clinical trials for hairy cell leukemia, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and hairy cell leukemia as inclusion criteria, 3 are phase 2 (3 open) .
Vemurafenib has evidence of efficacy in patients with BRAF mutation in hairy cell leukemia .
MYC is an inclusion eligibility criterion in 1 clinical trial for hairy cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYC status and hairy cell leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.